Zirconium Zr 89 Girentuximab clinical trials
Its developmentBy Telix Pharmaceuticals, step by step2 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Zirconium Zr 89 Girentuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Zirconium Zr 89 Girentuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 5
Institut Cancerologie de l'Ouest (2) · Telix Pharmaceuticals (Innovations) Pty Limited (2) · South Metropolitan Health Service (1) · Massachusetts General Hospital (1) · Jonsson Comprehensive Cancer Center (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Zirconium Zr 89 Girentuximab.
- Aug 2027CAIX PET/CT for Residual or Recurrent Post-ablative ccRCCPhase 2 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses Zirconium Zr 89 Girentuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- CAIX PET/CT for Residual or Recurrent Post-ablative ccRCCNot yet recruitingPhase 2Massachusetts General HospitalNCT07077083Written as 89Zr-Girentuximab
- An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT06447103Written as Zirconium Zr 89 Girentuximab
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyRecruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT06750419Written as 89Zr-TLX250 PET/CT
- Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast CancerCompletedPhase 2Institut Cancerologie de l'OuestNCT04758780Written as 89Zr-TLX250
- Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBCCompletedEarly Phase 1Institut Cancerologie de l'OuestNCT04897763Written as 89Zr-TLX250
- Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer PatientsCompletedPhase 1South Metropolitan Health ServiceNCT05046665Written as 89Zr-Girentuximab
- Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedPhase 1Telix Pharmaceuticals (Innovations) Pty LimitedNCT05861778Written as 89Zr-Girentuximab